ReviewPharmacoEconomics2019
Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
Review in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Medicaid Expansion and Overall Mortality Among Individuals With Renal Cell Carcinoma.The Journal of surgical research · 2026Article
- Noninvasive Differentiation of Indolent from Aggressive Renal Neoplasms with MR Fingerprinting Combined with Diffusion/Perfusion MRI.Radiology · 2026Article
- Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan.Frontiers in public health · 2026Article
- Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.ESMO real world data and digital oncology · 2025Article
- Article
- Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma.JAMA network open · 2024Article
- Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers.Frontiers in oncology · 2024Review
- Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment.Nature reviews. Urology · 2023Review
- Review
- Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.BJU international · 2022Article
- Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.Advances in therapy · 2021Article
- Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.Japanese journal of clinical oncology · 2020Observational
- Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.PharmacoEconomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011.
objectiveThe objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review.
methodsWe performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables.
resultsWe identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time.
conclusionRCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.